Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
CanSino Biologics, Inc. Class H ( (HK:6185) ) has provided an update.
CanSino Biologics Inc. has released its audited consolidated annual results for the year ended December 31, 2025, fulfilling disclosure requirements of the Hong Kong Stock Exchange for preliminary annual results announcements. The full annual report, including financial statements, management discussion and analysis, governance and auditor’s report, will be dispatched to shareholders and made available on the company’s and the exchange’s websites in due course, providing investors and other stakeholders with comprehensive insight into the company’s 2025 performance and governance.
The most recent analyst rating on (HK:6185) stock is a Hold with a HK$39.00 price target. To see the full list of analyst forecasts on CanSino Biologics, Inc. Class H stock, see the HK:6185 Stock Forecast page.
More about CanSino Biologics, Inc. Class H
CanSino Biologics Inc. is a China-incorporated biopharmaceutical company listed in Hong Kong, focused on the research, development and commercialization of vaccines and related biologic products. The firm operates through a board comprising executive, non-executive and independent non-executive directors, reflecting a standard Hong Kong–listed corporate governance structure.
Average Trading Volume: 944,254
Technical Sentiment Signal: Sell
Current Market Cap: HK$13.1B
For detailed information about 6185 stock, go to TipRanks’ Stock Analysis page.